What’s Hot in 2026: mRNA Beyond Vaccines

How the technology that drove our COVID-19 vaccines is redefining other areas of medicine. 

After proving its speed and scalability in the fight against infectious diseases, mRNA is stepping into new territory. Along with personalized cancer immunotherapies that target patient-specific tumor markers, researchers are also utilizing mRNA technology to develop treatments for rare genetic disorders previously considered untreatable and designing protein replacement therapies to restore essential functions in metabolic diseases. The possibilities extend even further to stimulating tissue repair in regenerative medicine and delivering advanced gene-editing tools, like CRISPR.

The key to success is speed and flexibility. mRNA drugs can be designed and manufactured in weeks rather than years, making them ideal for personalized medicine and rapid response. Their versatility is unmatched: mRNA can encode virtually any protein, opening doors to therapies that were only a dream a decade ago.

The next generation of RNA formats is already taking shape. Self-amplifying RNA promises longer-lasting effects with lower doses, while circular RNA offers greater stability and fewer immune reactions. Delivery systems are evolving beyond lipid nanoparticles to include lipoplexes, polyplexes, and even inhalable nanoparticles. Artificial intelligence is accelerating design, cutting development timelines by up to 70%.

Of course, challenges remain. Therapeutic applications demand precise dosing and controlled protein expression, which is far more complex than vaccine development. mRNAs are fragile and still require sophisticated carriers. Additionally, scaling personalized therapies while meeting stringent regulatory standards is a challenging task. There are also political concerns, including the decision this year by the US government to cancel $US800 million in federal funding for mRNA COVID vaccines. Whether this stance will eventually impact other applications for mRNA technology is unclear.

One thing is for sure: in 2026, mRNA is no longer just about preventive vaccines. It’s a modular, rapid-response platform poised to transform cancer care, rare disease treatment, and beyond.

-Ulrike Herbrand, Scientific Director of Global in vitro Assays